FDA DIVISION OF BLOOD AND BLOOD PRODUCTS WILL BE SPLIT
FDA DIVISION OF BLOOD AND BLOOD PRODUCTS WILL BE SPLIT into two independent divisions. Approved Aug. 29 by FDA Associate Commissioner for Management and Operations Sharon Holston, the reorganization establishes the Division of Transfusion Science and the Division of Hematology. The new Division of Transfusion Science will be headed on a permanent basis by Joel Solomon, MD, currently director of the Blood Products Division. Ann Hoppe will serve as deputy director. The Division of Hematology will be headed by acting director John Finlayson, PhD, the current Hepatitis Lab director, and acting deputy director Genesio Murano, PhD, until a permanent director and deputy director are selected. The Division of Transfusion Science, which becomes responsible for the review of HIV and hepatitis test kits and blood banking, will include the labs of Retrovirology, Hepatitis and Blood Banking Practices. They will be headed, by J. S. Epstein, MD, Robin Biswas, and Ann Hoppe, respectively. Hoppe will serve in an acting capacity. Among the responsibilities of the Division of Hematology will be the review of blood-derived drug products, such as growth factors, immunoglobulins, thrombolytics, and therapeutic monoclonal antibody products. Three pre-existing labs -- Cell Components, Plasma Derivatives, and Cell Biology -- will join the division and retain their current directors. In addition, a newly created Lab of Hemastasis & Thrombosis, will review thrombolytic agents and blood clotting factors. It will be headed by William Fricke from the Lab of Plasma Derivatives. Center for Biologics Evaluation and Research Acting Director Gerald Quinnan, MD, sent out a memo throughout CBER on Aug. 31 asking staff to "begin sending documents for product review to the appropriate division immediately." The realignment of Blood Products Division staff will take place during September; however, separate budgets for each division will not be designated until Oct. 1, the beginning of FY 1991.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: